Alveolar Bone Loss

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Geistlich Pharma
Geistlich PharmaSwitzerland - Root
1 program
1
Conventional protocolPhase 2/31 trial
Active Trials
NCT02120053Unknown37Est. Mar 2018
Vericel
VericelCAMBRIDGE, MA
1 program
1
Tissue Repair CellsPhase 1/21 trial
Active Trials
NCT00755911CompletedEst. May 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Geistlich PharmaConventional protocol
VericelTissue Repair Cells

Clinical Trials (2)

Total enrollment: 37 patients across 2 trials

NCT02120053Geistlich PharmaConventional protocol

Interest of Bone Substitute Material in Immediate Complete Denture

Start: Oct 2013Est. completion: Mar 201837 patients
Phase 2/3Unknown
NCT00755911VericelTissue Repair Cells

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

Start: Jun 2008Est. completion: May 2012
Phase 1/2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space